[1] 汪顺雨,刘庚英,杜忠东. 川崎病合并巨噬细胞活化综合征的临床研究进展[J]. 中华儿科杂志,2020,58(11):953-956. DOI:10.3760/cma.j.cn112140-20200407-00354.
[2] García-Pavón S, Yamazaki-Nakashimada MA, Báez M, et al. Kawasaki disease complicated with macrophage activation syndrome: a systematic review[J]. J Pediatr Hematol Oncol, 2017, 39(6): 445-451. DOI: 10.1097/ MPH.0000000000000872.
[3] See BT, Yip KX, Ang HL. Is coronary arteritis a feature in secondary haemophagocytic lymphohistiocytosis? [J]. Paediatr Int Child Health, 2018, 38(1): 76-79. DOI: 10.1080/20469047.2017.1289312.
[4] Sun G, Yao F, Yang Z. A pediatric case report of Epstein‑Barr virus‑associated hemophagocytic lymphohistiocytosis with pericardial effusion and multiple coronary artery aneurysms[J]. J Pediatr Hematol Oncol, 2021, 43(2): e219-e222. DOI: 10.1097/MPH.0000000000001642.
[5] Kato S, Yoshimura K, Tanabe Y, et al. A child with Epstein-Barr Virus-associated hemophagocytic lymphohistiocytosis complicated by coronary artery lesion mimicking Kawasaki disease [J]. J Pediatr Hematol Oncol, 2013, 35(7): e317-319. DOI: 10.1097/MPH.0b013e 31828e5281.
[6] Fukazawa R,Kobayashi J,Ayusawa M,et al. JCS/JSCS 2020 Guideline on diagnosis and management of cardiovascular se⁃quelae in Kawasaki disease[J]. Circ J,2020,84(8):1348-1407. DOI: 10.1253/circj.CJ-19-1094.
[7] Choi JE, Kwak Y, Huh JW, et al. Differentiation between incomplete Kawasaki disease and secondary hemophagocytic lymphohistiocytosis following Kawasaki disease using N‑terminal pro‑brain natriuretic peptide[J]. Korean J Pediatr, 2018, 61(5): 167-173. DOI: 10.3345/ kjp.2018.61.5.167.
[8] Wang W, Gong F, Zhu W, et al. Macrophage activation syndrome in Kawasaki disease: more common than we thought?[J]. Semin Arthritis Rheum, 2015, 44(4):405-410. DOI: 10.1016/j.semarthrit.2014.07.007.
[9] 王晓琳,王昭,王旖旎,等. 噬血细胞性淋巴组织细胞增多症44例预后相关因素分析[J]. 中华内科杂志,2011,50(4):333-334. DOI:10.3760/cma.j.issn.0578-1426.2011. 04.017.
[10] Crayne CB, Albeituni S, Nichols KE, et al. The immunology of macrophage activation syndrome[J]. Front Immunol, 2019, 10: 119. DOI: 10.3389/fimmu.2019.00119.
[11] Alongi A, Naddei R, De Miglio L, et al. Macrophage activation syndrome in pediatrics[J]. Pediatr Allergy Immunol, 2020, 31 Suppl 24: 13-15. DOI: 10.1111/ pai.13158.
[12] Chen Y, Shang S, Zhang C, et al. Hemophagocytic lymphohistiocytosis at initiation of kawasaki disease and their differential diagnosis[J]. Pediatr Hematol Oncol, 2010, 27(3): 244-249. DOI: 10.3109/08880011003623642.
[13] 周利兵. 川崎病并发巨噬细胞活化综合征的研究进展[J]. 临床儿科杂志,2018,36(10):796-800. DOI:10.3969/j.issn.1000-3606.2018.10.017.
[14] Aytaç S, Batu ED, Ünal Ş, et al. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus[J]. Rheumatol Int, 2016, 36(10): 1421-1429. DOI: 10.1007/s00296-016- 3545-9.
[15] Latino GA, Manlhiot C, Yeung RS, et al. Macrophage activation syndrome in the acute phase of Kawasaki disease[J]. J Pediatr Hematol Oncol, 2010, 32(7):527-531. DOI: 10.1097/MPH.0b013e3181dccbf4.
[16] Kang HR, Kwon YH, Yoo ES, et al. Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease [J]. Blood Res, 2013, 48(4): 254-257. DOI: 10.5045/br.2013.48.4.254.
|